Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2014-07-11

FDA Approved: WELLBUTRIN XL — Supplemental Application (Bausch Health US LLC)

View source ↗

Summary

The FDA approved a supplemental application for Wellbutrin XL (bupropion hydrochloride) submitted by Bausch Health US LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • WELLBUTRIN XL (Bupropion hydrochloride)

Snippet

SUPPL AP for WELLBUTRIN XL (BUPROPION HYDROCHLORIDE)